Literature DB >> 30243757

Mineralocorticoid receptor function and cognition in health and disease.

Katja Wingenfeld1, Christian Otte2.   

Abstract

The steroid hormone cortisol is released in response to stress and exerts its effects in the brain via two different receptors: the mineralocorticoid receptor (MR) and the glucocorticoid receptor (GR). This review - dedicated to Dirk Hellhammer - focusses on the role of MR on cognitive and emotional function in healthy individuals and in stress-associated disorders such as major depressive disorder (MDD) or borderline personality disorder (BPD). Animal data and studies from healthy individuals converge such that MR play an important role in the appraisal of new situations and the following response selection. Decision-making and empathy are important determinants of this response selection and both are affected by MR function. Furthermore, MR are crucially involved in visuospatial navigation and memory in young and elderly healthy individuals whereas the exact physiological role of MR in verbal learning and verbal memory needs to be further characterized. In contrast to studies in healthy participants, age played a moderating role on the effects of MR stimulation on cognition in depressed patients. In young depressed patients, MR stimulation exerted beneficial effects on verbal memory and executive function, whereas in elderly depressed patients MR stimulation led to impaired verbal learning and visuospatial memory. Similar to healthy controls, BPD patients showed enhanced emotional empathy but not cognitive empathy after MR stimulation. Accordingly, this make MR an interesting target for potential pharmacological augmentation of psychotherapy in BPD. Given the important role MR play in cognitive and emotional function in health and disease, further studies should examine whether MR modulation can alleviate cognitive and emotional problems in patients with stress-associated disorders.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Borderline personality disorder; Cognition; HPA axis; Major depressive disorder; Mental disorders; Mineralocorticoid receptor

Mesh:

Substances:

Year:  2018        PMID: 30243757     DOI: 10.1016/j.psyneuen.2018.09.010

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  13 in total

1.  The interplay between genetic variation and gene expression of the glucocorticoid receptor gene NR3C1 and blood cortisol levels on verbal memory and hippocampal volumes.

Authors:  Sandra Van der Auwera; Johanna Klinger-König; Katharina Wittfeld; Jan Terock; Anke Hannemann; Robin Bülow; Matthias Nauck; Uwe Völker; Henry Völzke; Hans Jörgen Grabe
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-05-17       Impact factor: 5.270

2.  Spironolactone as a potential new pharmacotherapy for alcohol use disorder: convergent evidence from rodent and human studies.

Authors:  Mehdi Farokhnia; Christopher T Rentsch; Vicky Chuong; M Adrienne McGinn; Sophie K Elvig; Eliza A Douglass; Luis A Gonzalez; Jenna E Sanfilippo; Renata C N Marchette; Brendan J Tunstall; David A Fiellin; George F Koob; Amy C Justice; Lorenzo Leggio; Leandro F Vendruscolo
Journal:  Mol Psychiatry       Date:  2022-09-20       Impact factor: 13.437

3.  The Characterization of Sex Differences in Hypoglycemia-Induced Activation of HPA Axis on the Transcriptomic Level.

Authors:  Serpil Taheri; Zuleyha Karaca; Minoo Rassoulzadegan; Ecmel Mehmetbeyoglu; Gokmen Zararsiz; Elif Funda Sener; Kezban Korkmaz Bayram; Esra Tufan; Mustafa Caglar Sahin; Mert Kahraman Marasli; Mehmet Memis; Halit Canatan; Figen Ozturk; Fatih Tanriverdi; Kursad Unluhizarci; Fahrettin Kelestimur
Journal:  Cell Mol Neurobiol       Date:  2021-02-05       Impact factor: 5.046

4.  Sex-Dependent Modulation of Acute Stress Reactivity After Early Life Stress in Mice: Relevance of Mineralocorticoid Receptor Expression.

Authors:  Valeria Bonapersona; Ruth Damsteegt; Mirjam L Adams; Lisa T C M van Weert; Onno C Meijer; Marian Joëls; Ratna Angela Sarabdjitsingh
Journal:  Front Behav Neurosci       Date:  2019-08-07       Impact factor: 3.558

5.  Steroid hormone secretion after stimulation of mineralocorticoid and NMDA receptors and cardiovascular risk in patients with depression.

Authors:  Jan Nowacki; Katja Wingenfeld; Michael Kaczmarczyk; Woo Ri Chae; Paula Salchow; Ikram Abu-Tir; Dominique Piber; Julian Hellmann-Regen; Christian Otte
Journal:  Transl Psychiatry       Date:  2020-04-20       Impact factor: 6.222

6.  Transcutaneous Auricular Vagus Nerve Stimulation-Paired Rehabilitation for Oromotor Feeding Problems in Newborns: An Open-Label Pilot Study.

Authors:  Bashar W Badran; Dorothea D Jenkins; Daniel Cook; Sean Thompson; Morgan Dancy; William H DeVries; Georgia Mappin; Philipp Summers; Marom Bikson; Mark S George
Journal:  Front Hum Neurosci       Date:  2020-03-18       Impact factor: 3.169

7.  Cognitive and emotional empathy after stimulation of brain mineralocorticoid and NMDA receptors in patients with major depression and healthy controls.

Authors:  Jan Nowacki; Katja Wingenfeld; Michael Kaczmarczyk; Woo Ri Chae; Ikram Abu-Tir; Christian Eric Deuter; Dominique Piber; Julian Hellmann-Regen; Christian Otte
Journal:  Neuropsychopharmacology       Date:  2020-07-28       Impact factor: 7.853

Review 8.  Cognitive Impairment in Heart Failure: Landscape, Challenges, and Future Directions.

Authors:  Mengxi Yang; Di Sun; Yu Wang; Mengwen Yan; Jingang Zheng; Jingyi Ren
Journal:  Front Cardiovasc Med       Date:  2022-02-07

9.  Loss of central mineralocorticoid or glucocorticoid receptors impacts auditory nerve processing in the cochlea.

Authors:  Philine Marchetta; Philipp Eckert; Robert Lukowski; Peter Ruth; Wibke Singer; Lukas Rüttiger; Marlies Knipper
Journal:  iScience       Date:  2022-02-26

10.  Effect of Glucocorticoid and 11β-Hydroxysteroid-Dehydrogenase Type 1 (11β-HSD1) in Neurological and Psychiatric Disorders.

Authors:  Seetal Dodd; David R Skvarc; Olivia M Dean; Anna Anderson; Mark Kotowicz; Michael Berk
Journal:  Int J Neuropsychopharmacol       Date:  2022-05-27       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.